If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 221 - 230 of 263

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Protocol No

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Selinexor is a medicine that is FDA approved for other cancer but not for endometrial cancer (EC). Selinexor was investigated in a prior study and demonstrated promising activity in a subgroup of patients with TP53 wild-type EC. To date there are no approved treatment options in the maintenance setting for patients with advanced or recurrent EC following response to chemotherapy. In this research study, we will investigate the safety and effectiveness of selinexor for maintenance in patients with TP53 wild-type endometrial cancer.
Protocol No